Blood cancer

FDA approves Imkeldi, imatinib as oral liquid, for certain leukemias

The U.S. Food and Drug Administration (FDA) has approved an oral liquid formulation of imatinib, now called Imkeldi, to treat specific forms of…

FDA approves revumenib for select acute leukemias with KMT2A defect

The U.S. Food and Drug Administration (FDA) has approved revumenib, now called Revuforj, as an oral therapy for children and adults, ages 1 year and…

Aucatzyl, a cell therapy, approved in US for adults with advanced B-ALL

The U.S. Food and Drug Administration (FDA) has approved the cell therapy Aucatzyl (obecabtagene autoleucel) to treat adults with relapsed or refractory precursor B-cell acute…